Immix Biopharma (IMMX) Equity Ratio (2020 - 2026)

Immix Biopharma has disclosed Equity Ratio across 7 years of filings, most recently posting 0.88 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.88, up 82.57% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.88 (up 82.57% YoY), and the FY2025 annual result was 0.89, up 54.93% from the prior year.
• Equity Ratio came in at 0.88 for Q1 2026 at Immix Biopharma, down from 0.89 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2022 to a low of 0.3 in Q2 2025.
• The 5-year median for Equity Ratio is 0.85 (2023), against an average of 0.77.
• Across the five-year window, Equity Ratio slumped 64.08% in 2025 and soared 82.57% in 2026, its largest moves.
• Immix Biopharma's Equity Ratio stood at 0.88 in 2022, then retreated by 7.88% to 0.81 in 2023, then fell by 28.99% to 0.58 in 2024, then soared by 54.93% to 0.89 in 2025, then fell by 1.58% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.89 (Q4 2025), and 0.41 (Q3 2025), per Business Quant data.